MYRIAD GENETICS - Dusseldorf Stock Exchang (MYD DU) stock market data APIs
€6.3704
-0.23(-3.6%)
as of September 18, 2025
Try our APIs with
free plan!
MYRIAD GENETICS - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for MYD.DU.
Prev. Close
6.3704
Open
6.1443
High
6.3704
Low
6.1443
52 wk Range
3.28-24.8
Market Cap
1 751 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MYRIAD GENETICS - Dusseldorf Stock Exchang data using free add-ons & libraries
Get MYRIAD GENETICS - Dusseldorf Stock Exchang Fundamental Data
MYRIAD GENETICS - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get MYRIAD GENETICS - Dusseldorf Stock Exchang Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get MYRIAD GENETICS - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MYRIAD GENETICS - Dusseldorf Stock Exchang News
New
3 Small-Cap Stocks That Concern Us
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside ri...
Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?
Myriad Genetics, Inc. MYGN is focused on expanding its companion diagnostics, driving market growth through new clinical guidelines, and introducing new offerings in its Oncology business. The company...
MYGN Stock Might Gain on The Lancet Study Backing Precise MRD
Myriad Genetics, Inc. MYGN recently announced that The Lancet Oncology has published a study demonstrating the performance of the company’s Precise MRD in patients with oligometastatic clear-cell re...
MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain?
Myriad Genetics, Inc. MYGN recently published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test over tr...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
